,8 Immune checkpoint therapy has brought a breakthrough in cancer therapy, and the programmed cell death 1 (PD1) antibody has been approved for the treatment of CRCs with high levels of microsatellite instability.3 This evidence concerns the gene PDCD1 and cancer.